Nxera Pharma Secures Lucerastat Rights in Japan and Select Asia-Pacific Markets
Nxera Pharma secured Lucerastat rights for Japan and selected Asia-Pacific markets for an upfront payment of 7 million francs.
Related stories
KOSPI Falls More Than 3% as AI Profitability Worries and Foreign Selling Weigh
The KOSPI fell more than 3% at the close, with AI profitability concerns and foreign selling cited; the index was down 16% for the month.
M impact | EQUITY | Oct 30, 2026, 07:07 AM UTC
ERIE Reports Fiscal Q3 Profit
ERIE reported fiscal third-quarter profit attributable to shareholders, up 3.39% year over year, and basic EPS.
M impact | EQUITY | Oct 30, 2026, 06:53 AM UTC
Japan’s Nikkei falls as much as 3% as chip stocks slide
Japan’s Nikkei share average fell as much as 3% on Friday, led by chip-related stocks, amid concerns about the sustainability of AI spending. The selloff followed overnight Wall St
M impact | EQUITY | Oct 30, 2026, 06:53 AM UTC
Japan's Nikkei Falls as Much as 3% on AI Concerns
Japanese technology stocks tumbled, weighing on the Nikkei; the body notes updates with closing prices and BOJ but gives no further details.
M impact | EQUITY | Oct 30, 2026, 06:53 AM UTC
EIX Reports Fiscal Q3 Profit, Down 32.69%
EIX reported fiscal third-quarter profit attributable to shareholders, down 32.69% year over year. Basic EPS was also reported.
M impact | EQUITY | Oct 30, 2026, 06:51 AM UTC
GoDaddy Reports Fiscal Q3 Net Profit
GoDaddy reported fiscal 2026 third-quarter profit attributable to shareholders, up 13.75% year over year, and basic EPS.
M impact | EQUITY | Oct 30, 2026, 06:51 AM UTC